Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

NCT00706628 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00706628
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00706628 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
Not reported
Enrollment
87 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic neoplasms